Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Neuropharmacology

• Publication date

  2014-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.neuropharm.2014.07.015PMID 25107586
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.

  2014cited by this paper
• Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.

  2014cited by this paper
• Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.

  2014cited by this paper
• Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.

  2014cited by this paper
• Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease

  2014cited by this paper
• The incretin hormones glucagonlike peptide 1 and glucose‐dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease

  2014cited by this paper
• Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.

  2014cited by this paper
• New and Emerging Drug Molecules Against Obesity

  2014cited by this paper
• Neuroprotective and anti‐apoptotic effects of liraglutide on SH‐SY5Y cells exposed to methylglyoxal stress

  2014cited by this paper
• A systematic review and meta‐analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes

  2014cited by this paper
• Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats.

  2014cited by this paper
• Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence

  2013cited by this paper
• Pharmacology, physiology, and mechanisms of incretin hormone action.

  2013cited by this paper
• Gut hormones as therapeutic agents in treatment of diabetes and obesity.

  2013cited by this paper
• The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain.

  2013cited by this paper
• Lixisenatide: First Global Approval

  2013cited by this paper
• Exenatide and the treatment of patients with Parkinson's disease.

  2013cited by this paper
• Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice.

  2013cited by this paper
• The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain

  2013cited by this paper
• Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice.

  2012cited by this paper
• Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

  2012cited by this paper
• The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-β Plaque and Glial Pathology in a Mouse Model of Alzheimer’s Disease

  2012cited by this paper
• Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.

  2012cited by this paper
• An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.

  2012cited by this paper
• glucagon-like peptide 1 analog liraglutide reduces TNF-- induced oxidative tress and inflammation in endothelial cells

  2012cited by this paper
• The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells.

  2012cited by this paper
• Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.

  2011cited by this paper
• The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test.

  2011cited by this paper
• Lixisenatide for type 2 diabetes mellitus

  2011cited by this paper
• Ischemia‐induced changes in glucagon‐like peptide‐1 receptor and neuroprotective effect of its agonist, exendin‐4, in experimental transient cerebral ischemia

  2011cited by this paper
• The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

  2011cited by this paper
• Glucose tolerance status and risk of dementia in the community

  2011cited by this paper
• The contribution of activated astrocytes to Aβ production: Implications for Alzheimer's disease pathogenesis

  2011cited by this paper
• Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.

  2011cited by this paper
• Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

  2011cited by this paper
• Enhancing the GLP‐1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells

  2010cited by this paper
• Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling.

  2010cited by this paper
• Synaptic Plasticity in the Hippocampus of a APP/PS1 Mouse Model of Alzheimer's Disease Is Impaired in Old but Not Young Mice

  2010cited by this paper
• Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary‐induced obesity and insulin resistance

  2010cited by this paper
• Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.

  2010cited by this paper
• Incretin-based therapies for type 2 diabetes mellitus

  2009cited by this paper
• Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system

  2009cited by this paper
• Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.

  2009cited by this paper
• Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.

  2009cited by this paper
• GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid.

  2008cited by this paper
• Seizures induced by GABAB-receptor blockade in early-life induced long-term GABA(B) receptor hypofunction and kindling facilitation.

  2008cited by this paper
• Small-molecule agonists for the glucagon-like peptide 1 receptor

  2007cited by this paper
• Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy.

  2007cited by this paper
• Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness.

  2007cited by this paper
• Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment.

  2007cited by this paper
• Neurodegeneration and neurogenesis: focus on Alzheimer's disease.

  2006cited by this paper
• Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain

  2006cited by this paper
• Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology

  2006cited by this paper
• Glucose metabolism and insulin receptor signal transduction in Alzheimer disease.

  2004cited by this paper
• Insulin and the insulin receptor in experimental models of learning and memory.

  2004cited by this paper
• Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron

  2003cited by this paper
• Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

  2003cited by this paper
• Pharmacological Agents That Directly Modulate Insulin Secretion

  2003cited by this paper
• Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

  2003cited by this paper
• Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier

  2002cited by this paper
• The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease

  2002cited by this paper
• Amyloid-Associated Neuron Loss and Gliogenesis in the Neocortex of Amyloid Precursor Protein Transgenic Mice

  2002cited by this paper
• Slow Degradation of Aggregates of the Alzheimer’s Disease Amyloid β-Protein by Microglial Cells*

  1997cited by this paper
• Synaptic release rather than failure in the conditioning pulse results in paired-pulse facilitation during minimal synaptic stimulation in the rat hippocampal CA1 neurones.

  1996cited by this paper
• Using paired-pulse facilitation to probe the mechanisms for long-term potentiation (LTP).

  1995cited by this paper
• Aging Neuroscience Review Article

  year unknowncited by this paper

• Therapeutic efficacy of synthetic analogues of gut hormones in a mouse model of Alzheimer's disease.

  2026cites this paper
• Potential Neuroprotective Role of GLP-2 in Alzheimer’s Disease: Clinical Observations, Mechanistic Insights, and Comparison with GLP-1

  2026cites this paper
• Large language models for Alzheimer's disease drug discovery

  2025cites this paper
• Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer’s Disease and Parkinson’s Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies

  2025cites this paper
• Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice

  2025cites this paper
• A novel Dual GLP-1/CCK Receptor Agonist Improves Cognitive Performance and Synaptogenesis in the 5 × FAD Alzheimer Mouse Model

  2025cites this paper
• Emerging Radioligands as Tools to Track Multi-Organ Senescence

  2025cites this paper
• Nanoscopic Mapping of the Extracellular Space in Amyloid Plaque‐rich Cortex

  2025cites this paper
• Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies

  2025cites this paper
• Insulin use in diabetes association with cognitive impairment and dementia incidence

  2025cites this paper
• Beyond diabetes and obesity: GLP‐1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation

  2025cites this paper
• Acupuncture for cognitive impairment in type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis protocol

  2025cites this paper
• Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer’s Disease

  2025cites this paper
• Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders.

  2025influential citation
• The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis

  2025cites this paper
• From Gut to Brain: The Role of Gut Dysbiosis, Bacterial Amyloids, and Metabolic Disease in Alzheimer's Disease.

  2025cites this paper
• Pathway-based network medicine identifies novel natural products for Alzheimer’s disease

  2025cites this paper
• The Effect of Glucagon-Like Peptide-1 and Glucose Dependent Insulinotropic Polypeptide Receptor Agonists on Neurogenesis, Differentiation and Plasticity: Potential Mechanistically-Informed Therapeutics in the Treatment and Prevention of Mental Disorders.

  2025cites this paper
• Refractory Nausea and Vomiting Due to Central Nervous System Injury: A Focused Review

  2025cites this paper
• Trial of Lixisenatide in Early Parkinson's Disease.

  2024cites this paper
• Impact of diabetes on the progression of Alzheimer’s disease via trajectories of amyloid–tau–neurodegeneration (ATN) biomarkers

  2024cites this paper
• In Vivo and Computational Studies on Sitagliptin’s Neuroprotective Role in Type 2 Diabetes Mellitus: Implications for Alzheimer’s Disease

  2024cites this paper
• Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP/PS1/tau mice.

  2024cites this paper
• Incretin Mimetics as Potential Disease Modifying Treatment for Alzheimer’s Disease

  2024cites this paper
• Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

  2024cites this paper
• Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges.

  2024cites this paper
• Pharmacotherapy for older people with obesity.

  2024cites this paper
• GLP-1/GIP Agonist as an Intriguing and Ultimate Remedy for Combating Alzheimer's Disease through its Supporting DPP4 Inhibitors: A Review.

  2024cites this paper
• Molecular mechanisms linking type 2 diabetes mellitus and late-onset Alzheimer's disease: A systematic review and qualitative meta-analysis.

  2024cites this paper
• A Cholecystokinin Analogue Ameliorates Cognitive Deficits and Regulates Mitochondrial Dynamics via the AMPK/Drp1 Pathway in APP/PS1 Mice

  2024cites this paper
• Cardiometabolic health, menopausal estrogen therapy and the brain: How effects of estrogens diverge in healthy and unhealthy preclinical models of aging

  2023cites this paper
• The impact of diabetes in cognitive impairment: A review of current evidence and prospects for future investigations

  2023cites this paper
• Promising new pharmacological targets for depression: the search for efficacy.

  2023cites this paper
• Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway.

  2023cites this paper
• The Microbiota–Gut–Brain Axis and Diabetic Cognitive Impairment: A Memorable Journey

  2023cites this paper
• Why to Study Peptides from Venomous and Poisonous Animals?

  2023cites this paper
• Crosstalk between Alzheimer’s disease and diabetes: a focus on anti-diabetic drugs

  2023cites this paper
• Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma

  2023cites this paper
• Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism

  2023influential citation
• Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus.

  2022cites this paper
• Current Insights on the Use of Insulin and the Potential Use of Insulin Mimetics in Targeting Insulin Signalling in Alzheimer’s Disease

  2022cites this paper
• Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases.

  2022cites this paper
• The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease

  2022cites this paper
• Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Neuroinflammation: Implications for Neurodegenerative Disease Treatment.

  2022cites this paper
• Psychiatric disorders and Type 2 diabetes mellitus: A bidirectional Mendelian randomization

  2022cites this paper
• Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions.

  2022cites this paper
• Incretin-based drugs as potential therapy for neurodegenerative diseases: Current status and perspectives.

  2022cites this paper
• The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review

  2022cites this paper
• DMSO_A_375559 2583..2597

  2022cites this paper
• The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors

  2022cites this paper
• Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities.

  2022cites this paper
• Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases

  2022cites this paper
• MicroRNA-206 down-regulated human umbilical cord mesenchymal stem cells alleviate cognitive decline in D-galactose-induced aging mice

  2022cites this paper
• Mechanistic and Etiological Similarities in Diabetes Mellitus and Alzheimer's Disease: Antidiabetic Drugs as Optimistic Therapeutics in Alzheimer's Disease.

  2022cites this paper
• GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight

  2022cites this paper
• Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease

  2022cites this paper
• Association Between Use of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors and Cognitive Function in a Longitudinal Study of Patients with Type 2 Diabetes

  2022cites this paper
• Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research

  2022cites this paper
• Causal association evaluation of diabetes with Alzheimer's disease and genetic analysis of antidiabetic drugs against Alzheimer's disease

  2022cites this paper
• Peganum harmala enhanced GLP-1 and restored insulin signaling to alleviate AlCl3-induced Alzheimer-like pathology model

  2021cites this paper
• New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs

  2021cites this paper
• Paracelsus' legacy in the faunal realm: drugs deriving from animal toxins.

  2021cites this paper
• Potential new therapeutic target for Alzheimer's disease: Glucagon‐like peptide‐1

  2021cites this paper
• Brain energy failure in dementia syndromes: Opportunities and challenges for glucagon‐like peptide‐1 receptor agonists

  2021cites this paper
• Liraglutide ameliorates diabetes-associated cognitive dysfunction via rescuing autophagic flux.

  2021cites this paper
• Glucagon-Like Peptide-1 Receptor Agonists and Brain Vascular Function.

  2021cites this paper
• Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus

  2021cites this paper
• A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer’s Disease

  2021cites this paper
• Contrasting Metabolic Insufficiency in Aging and Dementia

  2021cites this paper
• Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer’s Disease and Diabetes

  2021cites this paper
• Approach to Obesity in the Elderly.

  2021cites this paper
• Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders

  2021cites this paper
• Association between exenatide use and incidence of Alzheimer's disease

  2021cites this paper
• Targeting impaired nutrient sensing with repurposed therapeutics to prevent or treat age-related cognitive decline and dementia: a systematic review.

  2021cites this paper
• Therapies for Alzheimer's disease: a metabolic perspective.

  2021cites this paper
• Targeting Insulin Resistance to Treat Cognitive Dysfunction

  2021cites this paper
• Role of liraglutide in Alzheimer’s disease pathology

  2021cites this paper
• Effects of lixisenatide treatment on mild cachexia and related metabolic abnormalities in Walker‐256 tumour‐bearing rats

  2020cites this paper
• The novel GLP‐1/GIP analogue DA5‐CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD

  2020cites this paper
• Treatment With Liraglutide Exerts Neuroprotection After Hypoxic–Ischemic Brain Injury in Neonatal Rats via the PI3K/AKT/GSK3β Pathway

  2020cites this paper
• Lixisenatide Reduced Damage in Hippocampus CA1 Neurons in a Rat Model of Cerebral Ischemia-Reperfusion Possibly Via the ERK/P38 Signaling Pathway

  2020cites this paper
• Brain insulin resistance: role in neurodegenerative disease and potential for targeting

  2020cites this paper
• Insulin mediated novel therapies for the treatment of Alzheimer's disease.

  2020cites this paper
• Neurodegeneration in type 2 diabetes: Alzheimer's as a case study

  2020cites this paper
• Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience.

  2020cites this paper
• Type 2 Diabetes Mellitus Drugs for Alzheimer's Disease: Current Evidence and Therapeutic Opportunities.

  2020cites this paper
• Link between Diabetes and Alzheimer’s Disease Due to the Shared Amyloid Aggregation and Deposition Involving Both Neurodegenerative Changes and Neurovascular Damages

  2020cites this paper
• Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.

  2020influential citation
• Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases.

  2020cites this paper
• The Dual GLP-1/GIP Receptor Agonist DA4-JC Shows Superior Protective Properties Compared to the GLP-1 Analogue Liraglutide in the APP/PS1 Mouse Model of Alzheimer’s Disease

  2020cites this paper
• Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats.

  2020cites this paper
• Computational and Experimental Approaches to Design Inhibitors of Amylin Aggregation.

  2019cites this paper
• DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling.

  2019cites this paper
• The Full Spectrum of Alzheimer's Disease Is Rooted in Metabolic Derangements That Drive Type 3 Diabetes.

  2019cites this paper
• Prospective of managing impaired brain insulin signalling in late onset Alzheimers disease with excisting diabetic drugs

  2019cites this paper
• The Link Between Diabetes, Glucose Control, and Alzheimer's Disease and Neurodegenerative Diseases

  2019cites this paper
• Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer’s Disease

  2019influential citation
• Lixisenatide attenuates advanced glycation end products (AGEs)-induced degradation of extracellular matrix in human primary chondrocytes

  2019cites this paper
• GLP-1’s role in neuroprotection: a systematic review

  2019cites this paper
• Pharmacological Interventions to Attenuate Alzheimer's Disease Progression: The Story So Far.

  2019cites this paper